Prevalence and Impact of COVID-19 among Severe COPD Patients post Bronchoscopic Lung Volume Reduction Treatment with Endobronchial Valves.

Authors:
Klooster K; Hartman JE; Koster TD; Slebos DJ; van Dijk M.

Journal:
Respiration

Publication Year: 2022

DOI:
10.1159/000528610

PMCID:
PMC9843730

PMID:
36529120

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Respiration

Abbreviation: Respiration

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Photon Counting Computed Tomography with the Radiation Dose of a Chest X-Ray: Feasibility and Diagn…
Dettmer S; Werncke T; Mitkovska VN and 6 more (2024) - Transparency Score: 3/6
Bronchoscopic Evaluation of a Steerable Needle for Simulated Tumor Targets in the Lung Periphery: A…
Chen AC; Machuzak M; Cheng G and 1 more (2023) - Transparency Score: 3/6
Centrilobular Emphysema Is Associated with Pectoralis Muscle Reduction in Current Smokers without A…
Maetani T; Tanabe N; Shiraishi Y and 11 more (2023) - Transparency Score: 3/6
Evaluation of Bone Mineral Density in Lung Transplant Recipients by Chest Computed Tomography.
Mori R; Handa T; Ohsumi A and 16 more (2023) - Transparency Score: 3/6
Impact of Endobronchial Valve Treatment on Lung Function Decline.
Hartman JE; Klooster K; Koster TD and 3 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement Karin Klooster, Jorine Hartman, David Koster, and Marlies van Dijk have no conflicts. Dirk-Jan Slebos is an investigator, physician advisor, and consultant for Pulmonx Corp., CA, USA."

Evidence found in paper:

"The authors received no funding of any kind for this publication."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025